Moleculin Biotech CS (MBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -13,891 | -7,915 | -29,025 | -22,255 | -13,644 |
| Depreciation Amortization | 61 | 30 | 130 | 98 | 66 |
| Other Working Capital | 874 | 526 | 224 | 1,122 | 410 |
| Other Operating Activity | 1,813 | 1,342 | 1,032 | 652 | 362 |
| Operating Cash Flow | $-11,143 | $-6,017 | $-27,639 | $-20,383 | $-12,806 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -15 | N/A | -67 | -67 | -67 |
| Investing Cash Flow | $-15 | $N/A | $-67 | $-67 | $-67 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 211 | 141 | N/A | N/A | N/A |
| Other Financing Activity | -21 | 0 | -23 | -23 | -12 |
| Financing Cash Flow | $190 | $141 | $-23 | $-23 | $-12 |
| Exchange Rate Effect | -5 | -4 | -29 | -38 | -19 |
| Beginning Cash Position | 43,145 | 43,145 | 70,903 | 70,903 | 70,903 |
| End Cash Position | 32,172 | 37,265 | 43,145 | 50,392 | 57,999 |
| Net Cash Flow | $-10,973 | $-5,880 | $-27,758 | $-20,511 | $-12,904 |
| Free Cash Flow | |||||
| Operating Cash Flow | -11,143 | -6,017 | -27,639 | -20,383 | -12,806 |
| Capital Expenditure | -15 | N/A | -67 | -67 | -67 |
| Free Cash Flow | -11,158 | -6,017 | -27,706 | -20,450 | -12,873 |